PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2022-12-02 (5)

Date Title Company
02-Dec-2022 Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants Almirall
02-Dec-2022 Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s Eisai
02-Dec-2022 BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia BioXcel Therapeutics
02-Dec-2022 Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022 Achilles Therapeutics
02-Dec-2022 Diphtheria outbreak – the Government must drop its complacency and step-up testing, warns expert Diphtheria outbreak – the Government must drop its complacency and step-up testing, warns expert
02-Dec-2022 VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases
02-Dec-2022 Veeva Pulse Shows Europe HCP Access Averages 52% with Largest Growth in Content-Driven Digital Engagement Worldwide Veeva Pulse Shows Europe HCP Access Averages 52% with Largest Growth in Content-Driven Digital Engagement Worldwide
02-Dec-2022 Aptamer Group announces new deals to support novel therapies and improved assays Aptamer Group announces new deals to support novel therapies and improved assays
02-Dec-2022 Brooklands Innovation Academy inspires 400 STEM students Brooklands Innovation Academy
02-Dec-2022 Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Immunocore
02-Dec-2022 SmiLe strengthens team with international business expertise SmiLe
02-Dec-2022 Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer Businesswire